MIKHAIL BLAGOSKLONNY BELIEVING AND WORKING TOWARDS CANCER CURE

Is it possible to control ageing and cancer? Most would say no but Mikhail Blagosklonny, believes otherwise. He has keen interest is the field of ontology and is an author of many publication such as aging hyper function theory and has written about cyclotherapy of cell and chemotherapeutic engineering. Using Rapamycin Mikhail believes cancer can be cured.

His interest in the field of medicine did not start now, he went to Pavlov State Medical University of St. Petersburg and got an MD in internal medicine and further got a PH. D from the same university in Experimental Medicine and Cardiology.

It was in 2009, that Mikhail joined Roswell Park Cancer Institute as a professor of ontology. Previously he was a senior scientist at Ordway Research Institute not before he was working as an associate professor of medicine at New York Medical College. He is well experienced, and his work is on cancer, anti-aging drugs, Biogerontology (Aging Mechanism), and cancer therapies that are targeted and aim at protecting the healthy cells from damage.

Mikhail Blagosklonny has a hypothesis on TOR Signaling potential role in cancer and aging. To extend life, he suggest the use of Rapamycin a drug used in cancer treatment and in longevity research he is seen as the most passionate about the use of Rapamycin. His research is vast and includes ontogenesis, tumor suppression, and cell cycle and also involves cellular and molecular biology to investigations that are clinical.

His interest in finding a cure for cancer makes him best suited to teach at Roswell so as to share his findings and passion with the young minds. Roswell Park Cancer Institute (RPCI) started way back in 1898 and is located in Buffalo, New York, its main focus being cancer research and treatment.

In 2010, Mikhail together with Andrei V.Gudkov went ahead to start Oncotarget a weekly peer-review open access medical journal. Oncotarget is a term covering all molecules, cellular function, and pathways common in cancer and aging, atherosclerosis, lymphocytes, cancer cells, and neurodegeneration. Thus the paper aim is to make results that are scientific rapid and widely available. The success of the Oncotarget provides more avenues for research and cancer cure development, and this gives hope to cancer patients.

Visit this page: gettingstronger.org

Seattle Genetics to introduce more drugs under its CEO Clay Siegall

Seattle Genetics is a company that carries out research on cancer treatment. The company is currently under the leadership of Clay Siegall who serves as the CEO. Cancer drug testing and research organization covered by the company is comprehensive. Seattle aims a developing a new set of drugs that should focus on treatment of cancer. The number of people suffering from cancer has been on the rise. The Bothell-based company looks at their needs and helps them through introducing drugs that will be used to treat cancer.

The company has gone another step to higher employees. They will help in the testing of drugs and meet the huge production demand by the cancer drugs. Adcetris is the most sold drug by the company. The drug has gone through several trials to verify its effectiveness in treatment of lymphomas cells. The company has further conducted several clinical trials to show whether the drug can treat newly diagnosed cancers. Adcetris is a top of the line product. The product has made a significant impact on the company’s growth and revenue.

Cases of lymphomas are quite high in Canada and the US. Seattle Genetics has had the drug sell highly in both countries. The company is expecting to improve its sales as the market for the drug has grown in the current year.

Clay B. Siegall assisted in the co-founding of Seattle Genetics in 1998. He is today the company’s Chairman of the Board, Chief Executive Officer and President. A scientist by profession, he has had an emphasis on cancer treatment procedures. Dr. Siegall has built Seattle Genetics with the center foundation on rigorous research, innovation and drug development. His passion for helping patients has seen him do a lot in terms of research and product generation.

He played a lead role in guiding the company to produce the antibody drug conjugates and securing an approval from the FDA. Under collaboration with the Takeda Pharmaceuticals, Adcetris is today a global brand. It is approved in over 60 countries. Seattle Genetics is also advancing its line of ADCs for a better treatment of cancer.